WC
DOVA

Wexford Capital’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Wexford Capital’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,009
Closed -$299K – 185
2018
Q2 		$299K Buy
+10,009
New +$273K 0.02% 105

Other funds holding DOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Wexford Capital's DOVA Position: Q3 2018 in Review

Wexford Capital sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q3 2018, closing a stake of 10,009 shares — an estimated $299K sold.

Wexford Capital first reported a position in DOVA in Q2 2018 and held it in 1 quarter. The position peaked at $299K in Q2 2018. 63 funds tracked by Wall St. Rank hold DOVA as of Q3 2018.

  • Wexford Capital reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Wexford Capital sold 10,009 Dova Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $299K.
  • Wexford Capital first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Wexford Capital's Dova Pharmaceuticals, Inc. Common Stock position peaked at $299K in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on Wexford Capital's 13F filing for Q3 2018, filed 14 Nov 2018.